FOXO4-DRI Research Overview (also known as FOXO4-p53 peptide, Senolytic FOXO4 peptide, DRI-FOXO4)
A synthetic D-amino acid retro-inverso peptide designed to interfere with the FOXO4-p53 interaction that allows senescent cells to resist apoptosis. Studied for its potential to selectively clear senescent cells that accumulate with age and drive chronic inflammation and tissue dysfunction.
What Is FOXO4-DRI?
FOXO4-DRI is a D-amino acid retro-inverso peptide designed to selectively induce apoptosis in senescent cells — cells that have permanently exited the cell cycle but resist programmed death while actively secreting pro-inflammatory factors (the SASP: senescence-associated secretory phenotype). It is one of the first peptide-based senolytic compounds — agents that selectively clear senescent cells without harming normal healthy cells.
The Senescence Problem
Senescent cells accumulate with age and their SASP drives chronic tissue inflammation, impairs tissue repair, disrupts stem cell niches, and contributes to age-related pathology in virtually every organ system. Clearing senescent cells through senolytics has emerged as one of the most promising anti-aging strategies in modern biogerontology.
Mechanism and Research Findings
Senescent cells survive by upregulating FOXO4-p53 interaction, keeping p53 sequestered in the cytoplasm rather than the nucleus. FOXO4-DRI competitively binds FOXO4, displacing p53 and allowing it to initiate apoptosis — but only in senescent cells where this mechanism is active. In aged mice, FOXO4-DRI treatment produced restoration of fur density and appearance, increased exercise tolerance, improved renal function, and extended healthy lifespan — establishing proof-of-concept for targeted senolytic peptides.
Quick Reference
| Literature-Reported Dose Range | No established human dose. Anecdotal: ~25 mg |
| Literature-Reported Frequency | Every other day × 3 doses |
| Literature-Reported Cycle Length | 5 days (3 injections) |
| Literature-Reported Washout | Monthly cycles (anecdotal) |
| Storage | Lyophilized: -20°C. Reconstituted: 2-8°C |
| Sites Reported in Studies | SubQ: Abdominal fat |
| Timing | Cellular uptake 2-4 hours, persists 72+ hours |
Research Indications
Anti-Aging
Senescent Cell Clearance
Selectively eliminates senescent cells that accumulate with age
Tissue Rejuvenation
Mouse studies show restored tissue function in aged animals
Cellular Health
Cellular Health
Removes damaged cells to potentially allow regeneration
Inflammation
SASP Reduction
Eliminates cells producing inflammatory senescence factors
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Mouse Research Protocol | 5 mg/kg | Every other day × 3 | IV or IP |
| Conservative (Human) | 1.0 mg | Daily, 10–20 days | SubQ |
| Moderate (Human) | 3 mg | Every other day × 3 | SubQ |
| Aggressive (Human) | Up to 25 mg | Every other day × 3 | SubQ |
Timing
Conservative protocol: 1.0 mg daily for 10–20 days with a 1–6 month break between cycles. Moderate protocol: 3 mg every other day for 3 doses (6 days total), repeated 1–3× per year. Aggressive protocol: up to 25 mg every other day for 3 doses, 1–3× per year — reflects the anecdotal human translation of the mouse 5 mg/kg model. Mouse protocols use IV or IP administration; human research applications use SubQ only.
Peptide Interactions
Rapamycin may interfere with senolytic effects by modulating autophagy and cellular stress responses. A 1-2 week washout period is recommended before FOXO4-DRI administration.
Quercetin is itself a senolytic that works through different pathways. Concurrent use may diminish FOXO4-DRI effects. Minimum 96-hour washout, preferably 1-2 weeks.
Dasatinib + Quercetin is an alternative senolytic cocktail. Different mechanism than FOXO4-DRI. Sequential use may be considered but requires washout periods.
Corticosteroids may suppress the apoptotic cascade required for senolytic activity. Avoid concurrent use; washout period recommended.
Different mechanisms -Humanin protects healthy cells while FOXO4-DRI clears senescent ones. May be complementary in aging protocols.
Both target aging pathways but through different mechanisms. MOTS-C focuses on metabolic regulation. No interaction studies available.
Epitalon works through telomerase activation while FOXO4-DRI eliminates senescent cells. Theoretically complementary but no studies on combination.
5-Amino-1MQ has some senolytic properties through NNMT inhibition. Different mechanism. No data on concurrent use.
BPC-157 promotes tissue repair while FOXO4-DRI eliminates senescent cells. May be complementary for tissue regeneration but no studies available.
Mouse studies show FOXO4-DRI protects against doxorubicin-induced liver toxicity and may enhance tumor response when clearing senescent cells post-chemotherapy.
Reported Research Timeline
01No reliable human timeline
02Mouse studies: improvements in 1-4 weeks
03Fur and renal function restored in aged mice
04Human effects uncharacterized
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
No human clinical trials conducted
All safety data from mouse studies
Avoid Rapamycin, Quercetin, corticosteroids concurrently
Anecdotal: injection site reactions reported
p53 pathway involvement -theoretical oncogenic concerns
May not benefit healthy young individuals
Seek Medical Attention If:
Severe injection site reactions
Signs of immune activation
Unexplained fatigue or appetite loss
Quality Indicators
Acceptable Range
No human clinical data
All data from mouse studies. Human safety and efficacy unknown.
Acceptable Range
p53 pathway involvement
Targets critical tumor suppressor pathway. Long-term effects unknown.
Quality Concern
Avoid with Rapamycin/Quercetin
May diminish senolytic effects. 1-2 week washout required.
Verified Marker
High selectivity in studies
11.73-fold selectivity for senescent over healthy cells.
Research Citations
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Baar, M.P., Brandt, R.M., Putavet, D.A., Klein, J.D., Derks, K.W., Bourgeois, B.R., et al., 2017, Cell - FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
Zhang, L., Sun, J., Wang, B., Ren, J.C., Su, W., Zhang, T., 2020, Aging - Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Stegen, S., Rinzione, E., Ghubieda, S.M., De Vitto, H., Van den Berghe, G., Lim, K.S., 2021, Frontiers in Bioengineering and Biotechnology - FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway
Han, L., Zhang, Y., Liu, S., Zhao, Q., et al., 2022, Journal of Cellular and Molecular Medicine - FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice
Liu, Y., Wang, X., Zhang, H., et al., 2023, Naunyn-Schmiedeberg's Archives of Pharmacology - Development of a novel senolytic by precise disruption of FOXO4-p53 complex
Le, H.H., Cinaroglu, S.S., Manber, Z., et al., 2021, EBioMedicine - Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
Born E, Lipskaia L, Breau M, 2023, Circulation - FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
Kong YX, Li ZS, Liu YB, 2025, Commun Biol - Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Huang Y, He Y, Makarcyzk MJ, 2021, Front Bioeng Biotechnol - The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
Bourgeois B, Spreitzer E, Platero-Rochart D, 2025, Nat Commun - FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway
Han X, Yuan T, Zhang J, 2022, J Cell Mol Med
"
Research Focus
Senescent cell clearance, Senolytics, Aging, p53 pathway, Longevity, Cellular senescence
Verified Vendors Carrying FOXO4-DRI
Frequently Asked Questions
What should researchers watch for with FOXO4-DRI?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with FOXO4-DRI?
No reliable human timeline
How is FOXO4-DRI typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →